Disorders of Smell and Taste¶

Chapter 35 | Part 2: Cardinal Manifestations and Presentation of Diseases

KEY CLINICAL POINTS¶

Olfactory dysfunction affects >50% of people aged 65-80 years and 75% of those ≥ 80 years, with significant implications for nutrition, safety, and quality of life
The three most common causes of permanent smell loss are severe upper respiratory infections, head trauma, and chronic rhinosinusitis
Decreased smell function is among the first signs of neurodegenerative diseases including Parkinson's disease and Alzheimer's disease, often preceding motor symptoms by years
Most patients who complain of taste dysfunction actually have olfactory loss, as flavor perception depends primarily on retronasal olfactory stimulation
COVID-19 infection causes smell loss in many patients, with up to 30% failing to regain normal function even one year after diagnosis

1. DEFINITION & OVERVIEW¶

The senses of smell (olfaction) and taste (gustation) monitor environmental chemicals that enter the body through the nose and mouth. These chemosensory systems determine the flavor and palatability of foods and beverages, and provide critical warnings about dangerous environmental conditions including fire, air pollution, leaking natural gas, and bacteria-laden foodstuffs. These senses contribute significantly to quality of life and, when dysfunctional, can have serious physical and psychological consequences. A longitudinal study of 1162 nondemented elderly persons found that those with the lowest baseline olfactory test scores had a 45% mortality rate over a 4-year period, compared to an 18% mortality rate for those with the highest olfactory test scores. One of the most important recent developments in neurology is the discovery that decreased smell function is among the first signs of neurodegenerative diseases such as Parkinson's disease (PD) and Alzheimer's disease (AD), signifying their "presymptomatic" phase.

1.1 Terminology¶

Anosmia: Complete loss of smell
Hyposmia/Microsmia: Partial loss of smell (mild, moderate, or severe)
Dysosmia: Distorted smell perception
Phantosmia: Smell hallucinations (perceiving odors not present)
Ageusia: Complete loss of taste
Hypogeusia: Partial loss of taste
Dysgeusia: Distorted taste perception
Presbyosmia: Age-related decline in olfactory function

2. ANATOMY AND PHYSIOLOGY¶

Understanding the anatomic and physiologic basis of smell and taste is essential for diagnosing and managing chemosensory disorders.

2.1 Olfactory System Anatomy¶

Odorous chemicals enter the nose through two routes: - Front of nose: During inhalation and active sniffing - Back of nose (nasopharynx): During deglutition After reaching the highest recesses of the nasal cavity, odorants dissolve in olfactory mucus and diffuse or are actively transported by specialized proteins to receptors located on the cilia of olfactory receptor cells. The olfactory neuroepithelium covers: - Cribriform plate - Superior nasal septum - Superior turbinate - Sectors of the middle turbinate

2.2 Olfactory Receptor Cells¶

Nearly 400 types of G-protein-coupled odor receptors (GPCRs) are expressed on receptor cell cilia
Only one type of GPCR is expressed on a given cell
Additional receptors include trace amine-associated receptors and MS4A protein family members
This plethora of receptor cell types does not exist in any other sensory system
Receptor cells can be replaced by stem cells near the basement membrane, although replacement is often incomplete

2.3 Olfactory Bulb and Central Pathways¶

Pathway of olfactory information: 1. Receptor cell axons coalesce into bundles (fila) surrounded by ensheathing cells 2. Pass through cribriform plate to olfactory bulbs 3. Synapse with dendrites in glomeruli (spherical structures forming a distinct bulb layer) 4. Receptor cells expressing the same receptor type project to the same glomerulus Key cell types in olfactory bulb: - Mitral and tufted cells: Primary projection neurons - Periglomerular cells: Modulate mitral/tufted cell activity - Granule cells: Most numerous cells, largely GABAergic, receive inputs from central brain structures Central projections: - Primary Olfactory Cortex (POC): Piriform and entorhinal cortices - receives direct projections from olfactory bulb - Olfaction is unique in that initial afferent projections bypass the thalamus - Orbitofrontal cortex (OFC): Where odor identification largely occurs - Close anatomic ties with amygdala, hippocampus, and hypothalamus explain associations between odor perception and memory, motivation, arousal, autonomic activity, digestion, and sex

2.4 Taste System Anatomy¶

Taste buds are specialized receptor structures located on: - Lateral margins and dorsum of tongue - Roof of mouth - Pharynx - Larynx - Superior esophagus Lingual taste buds are embedded in three types of papillae: - Fungiform papillae (anterior tongue) - Foliate papillae (lateral tongue) - Circumvallate papillae (posterior tongue) Humans have approximately 7500 taste buds, though not all harbor taste-sensitive cells. The number of taste receptor cells per taste bud ranges from zero to well over 100.

2.5 Taste Receptors¶

Basic taste qualities and their receptors: - Sweet and Umami: T1R receptors (T1R1, T1R2, T1R3) - a family of 3 GPCRs - Bitter: T2R receptors - a family of ~30 GPCRs expressed on cells different from sweet/umami receptors; sense wide range of bitter substances but do not distinguish among them - Sour: PKD2L1 receptor - a member of the transient receptor potential protein (TRP) family - Salty: Entry of Na+ ions via specialized membrane channels (e.g., amiloride-sensitive Na+ channel) Important: Bitter and sweet taste-related receptors are also present elsewhere in the body, notably in the alimentary and respiratory tracts. α -gustducin (taste-specific G-protein α -subunit) is expressed in brush cells in the trachea, lung, pancreas, and gallbladder.

2.6 Taste Neural Pathways¶

Three cranial nerves carry taste information: - CN VII (Facial nerve): Via intermediate nerve branches (greater petrosal and chorda tympani nerves) - Innervates anterior tongue and all of soft palate - Chorda tympani courses through facial canal, middle ear, exits via petrotympanic fissure - Also carries parasympathetic fibers to submandibular and sublingual glands - CN IX (Glossopharyngeal nerve): Innervates posterior tongue - CN X (Vagus nerve): Innervates laryngeal surface of epiglottis, larynx, and proximal esophagus - CN V (Trigeminal nerve - mandibular branch): Conveys somatosensory information (touch, burning, cooling, irritation) - adds temperature, texture, pungency, and spiciness to taste experience Central pathways: 1. Projection cells synapse in rostral nucleus of the solitary tract (NTS) in medulla 2. Neurons project to ventroposteromedial thalamic nucleus (VPM) via medial lemniscus 3. Projections to primary taste cortex (PTC): rostral frontal operculum and adjoining insula 4. Secondary taste cortex: caudolateral orbitofrontal cortex (OFC) - involved in conscious recognition of taste qualities and establishing "flavor"

3. EPIDEMIOLOGY¶

Estimates of olfactory dysfunction prevalence vary, but the impact increases dramatically with age.

3.1 Prevalence of Olfactory Dysfunction¶

Overall prevalence: 13.5% (NHANES 2013-2014 cross-sectional analysis)
Ages 65-80 years: >50% have significant decrements in smell ability
Ages ≥ 80 years: 75% have significant decrements
Women typically outperform men on olfactory tests and retain normal function to a later age Presbyosmia (age-related smell loss) explains why:
Many elderly report food has little flavor
Nutritional disturbances are common in elderly
Disproportionate numbers of elderly die in accidental gas poisonings

3.2 Common Causes of Smell Loss¶

The three most common identifiable causes of long-lasting or permanent smell loss (in order of frequency): 1. Severe upper respiratory infections 2. Head trauma 3. Chronic rhinosinusitis

4. ETIOLOGY AND PATHOPHYSIOLOGY¶

Chemosensory dysfunction can result from numerous conditions affecting different levels of the sensory pathways.

Disorders and Conditions Associated with Compromised Olfactory Function¶

Category	Conditions
Endocrine/Metabolic	Addison's disease, Turner's syndrome, Cushing's syndrome, Diabetes, Hypertension, Hypothyroidism, Kallmann's syndrome, Liver disease, Renal failure, Pregnancy, Pseudohypoparathyroidism, Wilson's disease
Immune-Related	Allergic rhinitis, Asthma, Behçet's disease, Cystic fibrosis, Giant cell arteritis, Inflammatory bowel diseases, Lupus, Multiple sclerosis, Myasthenia gravis, Rheumatoid arthritis, Sjögren's syndrome, Wegener's granulomatosis
Nasosinus Disorders	Adenoid hypertrophy, Bacterial/viral upper respiratory infections, Laryngopharyngeal reflux disease, Rhinosinusitis/polyposis
Neurologic	Alzheimer's disease, ALS, Bell's palsy, Down's syndrome, Epilepsy, Frontotemporal degeneration, Head trauma, Huntington's disease, Migraine, Multi-infarct dementia, Parkinson's disease, REM behavioral sleep disorder, Stroke
Psychiatric	Anorexia nervosa, Attention deficit/hyperactivity disorder, Depression, Obsessive compulsive disorder, Panic disorder, PTSD, Schizophrenia
Infections	Candidiasis, COVID-19, Hepatitis C, HIV, Legionnaires' disease, Leprosy, Lyme disease, Poliomyelitis, Upper respiratory infections
Other Factors	Alcoholism, Chemical/toxic exposure, Congenital, Chemotherapy/radiation, Nutritional deficiencies, Obesity, Tobacco smoking, Vitamin B12 deficiency

4.1 Mechanisms of Olfactory Dysfunction¶

Head Trauma: - Primary mechanism: Shearing and subsequent scarring of olfactory fila as they pass from nasal cavity into brain cavity - Cribriform plate does NOT have to be fractured for smell loss to occur - Severity correlates with poor Glasgow Coma Scale score and length of posttraumatic amnesia - Prognosis: <10% of anosmic patients recover age-related normal function; ~25% of those with partial loss recover Respiratory Infections: - Direct permanent damage to olfactory epithelium - Decreased receptor cell number - Damage to cilia on remaining receptor cells - Replacement of sensory epithelium with respiratory epithelium - COVID-19: Smell loss often independent of nasal inflammation; up to 30% fail to regain normal function at 1 year; 5-10% experience total loss Chronic Rhinosinusitis: - Smell loss related to disease severity - Most loss occurs when rhinosinusitis AND polyposis are both present - Systemic glucocorticoids can induce short-term improvement but do not return scores to normal, implying chronic permanent neural loss - Microinflammation in seemingly normal epithelium can influence smell function

4.2 Neurodegenerative Diseases¶

Diseases associated with olfactory impairment: - Parkinson's disease (PD) - Alzheimer's disease (AD) - Huntington's disease - Parkinsonism-dementia complex of Guam - Dementia with Lewy bodies (DLB) - Multiple system atrophy - Corticobasal degeneration - Frontotemporal dementia - Down's syndrome - Idiopathic REM behavioral sleep disorder (iRBD) - Multiple sclerosis (related to lesions in olfaction-related structures) Key Points: - Olfactory impairment in PD often predates clinical diagnosis by years - Olfactory bulbs may be, along with dorsomotor nucleus of vagus, the first site of neural damage in PD - In postmortem studies of mild "presymptomatic" AD, poorer smell function associated with higher levels of AD-related pathology - Smell loss more marked in early DLB than in mild AD - Smell loss is minimal or nonexistent in progressive supranuclear palsy and MPTP-induced parkinsonism iRBD and Narcolepsy: - iRBD: Smell loss of same magnitude as PD; patients frequently develop PD and hyposmia - Narcolepsy with cataplexy: Associated with olfactory impairment independent of REM behavior disorder - Orexin (hypocretin)-containing neurons project throughout entire olfactory system - Intranasal orexin A improved olfactory function in narcolepsy

4.3 Mechanisms of Taste Dysfunction¶

Factors influencing taste function: 1. Release of foul-tasting materials from oral conditions (gingivitis, purulent sialadenitis) or appliances 2. Transport problems of tastants to taste buds (drying, infections, inflammatory conditions) 3. Damage to taste buds (local trauma, invasive carcinomas) 4. Damage to neural pathways (middle ear infections) 5. Damage to central structures (multiple sclerosis, tumor, epilepsy, stroke) 6. Systemic metabolic disturbances (diabetes, thyroid disease, medications) CN-Specific Injuries: - CN IX: Relatively protected; may be damaged by tonsillectomy, bronchoscopy, laryngoscopy, endotracheal intubation, radiation therapy - CN VII: Commonly damaged by mastoidectomy, tympanoplasty, stapedectomy (may cause persistent metallic sensations); Bell's palsy is a common cause Special Conditions: - Migraine: Occasionally associated with gustatory prodrome or aura; tastants can trigger attacks - Burning mouth syndrome: Associated with dysgeusia, dry mouth, and thirst; likely associated with CN V dysfunction

5. CLINICAL FEATURES¶

The presentation of chemosensory disorders varies based on the underlying etiology and affected sensory system.

5.1 Olfactory Dysfunction Presentations¶

Types of olfactory complaints: - Quantitative: Anosmia (complete loss), hyposmia (partial loss) - Qualitative: Dysosmia (distortion), phantosmia (hallucination) Patterns suggesting etiology: - Sudden loss: Head trauma, ischemia, infection, psychiatric condition - Gradual loss: Progressive obstructive lesion (can also follow head trauma) - Intermittent loss: Inflammatory process Associated features to assess: - Epistaxis, nasal discharge (clear, purulent, bloody) - Nasal obstruction - Allergies - Headache or irritation - Memory problems - Parkinsonian symptoms - Seizure activity (automatisms, blackouts, auras, déjà vu)

5.2 Taste Dysfunction Presentations¶

Important: The majority of patients presenting with taste dysfunction actually exhibit olfactory, not taste, loss. This is because most flavors attributed to taste depend on retronasal stimulation of olfactory receptors during deglutition. True taste dysfunction: - Rare outside of generalized metabolic disturbances or systemic medication use - Taste bud regeneration occurs - Peripheral damage alone would require involvement of multiple CN pathways Specific presentations: - Metallic taste: CN VII damage (post-surgical) - Dysgeusia: Drug-related (>250 medications implicated), cancer treatment (56-76% prevalence depending on treatment type) - Burning mouth syndrome: Associated with CN V dysfunction, dry mouth, thirst

5.3 Special Populations¶

Elderly: - Presbyosmia contributes to reports of food having little flavor - Nutritional disturbances common - Increased risk of accidental gas poisoning Pregnancy: - Increased dislike and intensity of bitter tastes in first trimester (protective against poisons during critical fetal development) - Relative increase in salt and bitter preference in second and third trimesters (supports electrolyte ingestion and varied diet) Diabetes: - Progressive taste loss: begins with glucose → other sweeteners → salty stimuli → all stimuli Kallmann's Syndrome: - Anosmia + delayed puberty ± midline craniofacial abnormalities, deafness, renal anomalies

6. DIFFERENTIAL DIAGNOSIS¶

A systematic approach to differential diagnosis helps identify the underlying etiology of chemosensory complaints.

6.3 Burning Mouth Syndrome Etiologies¶

Amenable to treatment: - Nutritional deficiencies (iron, folic acid, B vitamins, zinc) - Diabetes mellitus (may predispose to oral candidiasis) - Denture allergy - Mechanical irritation from dentures or oral devices - Repetitive mouth movements (tongue thrusting, teeth grinding, jaw clenching) - Tongue ischemia from temporal arteritis - Periodontal disease - Reflux esophagitis - Geographic tongue

7. INVESTIGATIONS AND DIAGNOSIS¶

A comprehensive evaluation includes history, examination, imaging, laboratory tests, and quantitative sensory testing.

UPSIT Classification of Olfactory Function¶

Classification	Description
Normosmia	Normal olfactory function for age and gender
Mild Microsmia	Mildly reduced olfactory function
Moderate Microsmia	Moderately reduced olfactory function
Severe Microsmia	Severely reduced olfactory function
Anosmia	Complete loss of olfactory function
Probable Malingering	Improbable response pattern suggesting feigned dysfunction

7.1 Clinical History¶

Essential history elements: - Nature, onset, duration, and pattern of fluctuations - Precipitating events (cold/flu infections often go underappreciated) - Head trauma history - Smoking habits - Drug and alcohol abuse (intranasal cocaine, chronic alcoholism) - Exposures to pesticides and other toxic agents - Medical interventions - Complete medication list (before and at time of symptom onset) - Comorbid conditions (renal failure, liver disease, hypothyroidism, diabetes, dementia) - Pending litigation (consider malingering)

7.2 Physical Examination¶

Neurologic Examination: - Focus on cranial nerve function - Attention to skull base and intracranial lesions - Visual acuity, visual field, and optic disc examination - Papilledema: indicates raised intracranial pressure - Optic atrophy: suggests compressive lesion - Foster Kennedy syndrome: Raised ICP + compressive optic neuropathy (olfactory groove meningiomas, frontal lobe tumors) Otorhinolaryngologic Examination: - Thorough assessment of intranasal architecture and mucosal surfaces - Identify polyps, masses, adhesions of turbinates to septum - Note: <1/5 of inspired air traverses olfactory cleft in unobstructed state

7.3 Laboratory Tests¶

Blood tests to identify: - Diabetes - Infection - Heavy metal exposure - Nutritional deficiency (vitamin B6 or B12) - Allergy - Thyroid disease - Liver disease - Kidney disease

7.4 Imaging¶

Brain MRI: Evaluate for intracranial mass lesions, neurodegenerative changes, olfactory bulb pathology
Nasosinus imaging: CT or MRI to assess for obstructive pathology, sinusitis, polyps

7.5 Quantitative Sensory Testing¶

Rationale for testing: - Self-reports can be misleading - Some patients complaining of dysfunction have normal function for age/gender - Provides objective information for worker's compensation and legal claims - Allows accurate assessment of treatment effects - Modern forced-choice tests can detect malingering from improbable responses Olfactory Testing: - University of Pennsylvania Smell Identification Test (UPSIT): Most widely used; 40-item test with norms based on >10,000 subjects - Provides classification: Normosmia, Mild/Moderate/Severe Microsmia, Anosmia, Probable Malingering - Determines percentile rank for age and gender - Electrophysiologic testing (odor event-related potentials): Available at some centers but rarely provides additional diagnostic information Taste Testing: - Electrogustometers - Filter paper strips impregnated with tastants (recently commercially available)

8. MANAGEMENT AND TREATMENT¶

Treatment approaches are condition-specific and range from addressing underlying causes to symptomatic management.

8.1 Treatment of Underlying Conditions¶

Systemic Diseases: - Hypothyroidism: Thyroid hormone replacement - Diabetes: Glycemic control - Infections: Appropriate antimicrobial therapy Obstructive/Transport Loss: - Allergic rhinitis, polyposis, intranasal neoplasms, nasal deviations: Medical and/or surgical intervention - Endoscopic sinus surgery: Patients with severe olfactory dysfunction pre-operatively show more dramatic and sustained improvement Oral Infections: - Candidiasis: Antifungal treatment - Other oral infections: Appropriate antibiotics - Chlorhexidine mouthwash: May mitigate salty or bitter dysgeusias

8.2 Glucocorticoid Therapy¶

Indications: - Intranasal and sinus-related inflammatory conditions (allergy, viruses, trauma) - Chronic rhinosinusitis - Post-head trauma (to reduce edema and scar tissue deposition around olfactory fila) Administration: - Systemic: Tapering course of oral prednisone (generally more effective than topical) - Intranasal: More effective if administered in Moffett's position (head inverted over edge of bed, bridge of nose perpendicular to floor) Limitations: - In rhinosinusitis, systemic glucocorticoids induce short-term improvement but do NOT return scores to normal on average - Implies chronic permanent neural loss and/or incomplete inflammation mitigation

8.3 Management of Oral Dryness¶

Artificial saliva (e.g., Xerolube)
Oral pilocarpine
Mints, lozenges, sugarless gum to improve salivary flow

Discontinue offending medications and replace with alternatives when possible
Many drug-related effects are long-lasting and not reversed by short-term discontinuance
Intranasal zinc-containing gels/sprays for URI prophylaxis have been implicated in smell loss Cancer Treatment-Related Dysgeusia:
Weighted prevalence: 56-76% depending on treatment type
Prophylactic zinc sulfate or amifostine: Minimally beneficial

8.5 Olfactory Training¶

Several studies suggest hyposmic patients may benefit from repeated odor exposure: Protocol: - Smell odors such as eucalyptol, citronella, eugenol, and phenyl ethyl alcohol - Before going to bed AND immediately upon awakening each day - Continue for weeks to months Rationale: - Animal studies demonstrate prolonged odorant exposure can induce increased neural activity in olfactory bulb Limitation: - Remains to be determined how much improvement occurs beyond spontaneous recovery

8.6 Pharmacologic Interventions¶

Limited evidence for efficacy: α -Lipoic Acid (400 mg/day): - Essential cofactor for many enzyme complexes with possible antioxidant effects - May be beneficial in mitigating smell loss following viral URI - Also suggested for hypogeusia and burning mouth syndrome - Double-blind studies needed Zinc and Vitamin A: - Controversial; no benefit beyond replenishing established deficiencies - Zinc shown to improve taste function secondary to hepatic deficiencies - Retinoids (bioactive vitamin A derivatives) play essential role in olfactory neuron survival - Zinc infused with chemotherapy may have protective effect against taste impairment Vitamin B12: - Alimentary tract diseases can influence absorption - Relative deficiency may contribute to olfactory nerve disturbance Vitamin B2 (Riboflavin) and Magnesium: - Reported in alternative literature to aid migraine management, which may be associated with smell dysfunction Vitamin D (1000-2000 units/day): - Deficiency is cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia - May benefit patients with smell/taste complaints during or following chemotherapy Theophylline: - One uncontrolled report suggested improvement - Failed to account for spontaneous improvement (~50% responders, similar to natural improvement rate) Antiepileptics and Antidepressants (e.g., amitriptyline): - Used to treat dysosmias and smell distortions, particularly following head trauma - Ironically, amitriptyline can also distort smell and taste function (anticholinergic effects) Donepezil: - One study suggested improvements in smell identification in AD correlating with overall improvement in dementia severity scores

8.7 Dietary and Lifestyle Modifications¶

Flavor Enhancement: - Monosodium glutamate (MSG) can increase palatability - Caution: Avoid overusing ingredients with sodium or sugar in patients with hypertension or diabetes Optimizing Eating Experience: - Accentuate other sensory experiences: food texture, aroma, temperature, color Oral and Nasal Hygiene: - Proper hygiene and routine dental care protect against disorders causing chemosensory dysfunction

8.8 Alternative Therapies¶

May help patients manage uncomfortable experiences: - Acupuncture - Meditation - Cognitive-behavioral therapy - Yoga Benefits: - Help cope with psychosocial stressors surrounding impairment - Manage oral pain syndromes

9. PROGNOSIS AND COMPLICATIONS¶

Outcomes depend heavily on the etiology and severity of chemosensory dysfunction at presentation.

9.1 Natural History and Prognosis¶

General Prognosis (follow-up study of 542 patients): - Modest improvement occurred in about half of participants over average 4 years - Only 11% of anosmic patients regained normal age-related function - Only 23% of hyposmic patients regained normal function Best Predictors of Prognosis: 1. Amount of dysfunction at presentation (most important) 2. Age 3. Duration of dysfunction prior to initial testing Note: Etiology was NOT the best predictor of outcome Etiology-Specific Prognosis: Head Trauma: - <10% of anosmic patients recover age-related normal function - ~25% of those with partial loss recover COVID-19: - Up to 30% fail to regain normal function at 1 year - 5-10% experience total loss

9.2 Complications of Chemosensory Dysfunction¶

Safety Risks: - Failure to detect fire, smoke, gas leaks - Inability to identify spoiled food - Accidental gas poisoning (especially elderly) Nutritional Consequences: - Decreased food palatability leading to poor intake - Weight loss and nutritional deficiencies Quality of Life: - Depression and anxiety - Social isolation - Decreased enjoyment of meals and social eating Mortality: - Lowest olfactory test scores: 45% mortality over 4 years - Highest olfactory test scores: 18% mortality over 4 years

10. SPECIAL CONSIDERATIONS¶

Certain populations and conditions require special attention in the evaluation and management of chemosensory disorders.

10.1 Elderly Patients¶

Presbyosmia is extremely common (>50% ages 65-80; 75% age ≥ 80)
Higher risk of nutritional disturbances
Higher risk of accidental gas poisoning
Consider early neurodegenerative disease screening if smell loss disproportionate to age

10.2 Pregnancy¶

First trimester: Increased dislike and intensity of bitter tastes (protective mechanism)
Second and third trimesters: Relative increase in salt and bitter preference
These changes serve physiologic purposes and typically resolve postpartum

10.3 Neurodegenerative Disease Screening¶

Consider in patients with unexplained smell loss: - Parkinson's disease evaluation (motor examination, dopamine transporter imaging) - Alzheimer's disease evaluation (cognitive testing, biomarkers) - Sleep study if REM behavioral sleep disorder suspected - Olfactory dysfunction may precede motor or cognitive symptoms by years

10.4 Legal and Occupational Considerations¶

Quantitative testing essential for worker's compensation claims
Forced-choice olfactory tests can detect malingering
Document baseline function and track changes over time

11. KEY POINTS AND CLINICAL PEARLS¶

Clinical Pearls for Chemosensory Disorders¶

Category	Key Point
Diagnosis	Most patients complaining of taste loss actually have olfactory dysfunction - test smell first
Diagnosis	Sudden onset suggests trauma, ischemia, infection, or psychiatric cause; gradual onset suggests progressive lesion; intermittent loss suggests inflammation
History	Ask specifically about preceding URI - patients often underappreciate this association
Examination	Foster Kennedy syndrome (papilledema + optic atrophy) suggests olfactory groove meningioma or frontal lobe tumor
Testing	Self-reports are unreliable - always perform quantitative sensory testing
Testing	Modern forced-choice tests can detect malingering through improbable response patterns
Prognosis	Severity at presentation, not etiology, is the best predictor of recovery
Treatment	Intranasal glucocorticoids are more effective when administered in Moffett's position

Category	Key Point
Treatment	Many drug-related chemosensory effects are long-lasting and not reversed by short-term discontinuation
Neurology	Smell loss is an early marker of Parkinson's and Alzheimer's disease - consider screening
Neurology	iRBD patients with smell loss are at high risk for developing Parkinson's disease
Safety	Elderly patients with smell loss are at high risk for accidental gas poisoning - counsel about safety measures
Medications	>250 medications can alter taste - obtain complete medication history
COVID-19	Smell loss is often independent of nasal inflammation; up to 30% have persistent dysfunction at 1 year